文献速递其他结缔组织病

抗MDA5抗体临床特征与临床一致性:澳大利亚多中心研究

Clinical Characteristics and Concordance of Anti-MDA5 Antibodies: A Multicenter Australian Study.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2026-08-17

该多中心研究纳入澳大利亚三州2017年1月至2024年9月线免疫印迹法(LIA)抗MDA5阳性患者,118例中108例有完整临床资料。仅19.4%(21/108)判定为临床一致,且一致者LIA信号强度更高;抗MDA5皮肌炎患者均合并间质性肺病(ILD),快速进展型ILD(RP-ILD)病死率高,纵隔气肿常见。

要点

  • LIA抗MDA5阳性者仅约19.4%临床一致,信号强度较高者更可能一致。
  • 抗MDA5皮肌炎患者全部合并ILD,RP-ILD者病死率高。
  • 纵隔气肿在抗MDA5皮肌炎中常见,且与高病死率相关。

核心结论

  • LIA抗MDA5信号强度较高与更高的临床一致性相关。
  • 抗MDA5皮肌炎中纵隔气肿常见,并与高病死率相关。

研究设计与样本

  • 澳大利亚三州多中心队列,回顾2017年1月至2024年9月LIA抗MDA5阳性患者电子病历。
  • 118例抗MDA5阳性患者中108例有完整临床资料可供分析。

主要发现

  • 108例中21例(19.4%)抗MDA5阳性判定为临床一致,其信号强度高于临床不一致者(52 vs 19.5;P<0.0001)。
  • 21例抗MDA5皮肌炎患者均合并ILD;9例RP-ILD中7例在资料回顾时已死亡。
  • RP-ILD者铁蛋白(1,226 vs 262 μg/L;P<0.05)及中性粒细胞与淋巴细胞比值(4.1 vs 2.6;P<0.05)高于非RP-ILD者。
  • 纵隔气肿发生于21例中的7例(33%),其中6例合并RP-ILD,4例随后死亡。
  • 其他表现包括肌炎(n=8)、皮肤表现(n=14)、多关节炎(n=6)和心肌炎(n=1)。

关键数值与推荐

  • 抗MDA5阳性临床一致者LIA信号强度52,不一致者19.5(P<0.0001)。
  • 抗MDA5皮肌炎队列中位年龄65岁(四分位距48-74),女性占67%。
  • RP-ILD者铁蛋白1,226 vs 262 μg/L(P<0.05),中性粒细胞与淋巴细胞比值4.1 vs 2.6(P<0.05)。

临床怎么用

  • 对LIA抗MDA5阳性结果应结合临床判断一致性,信号强度较高者更需警惕抗MDA5皮肌炎。
  • 抗MDA5皮肌炎患者应评估ILD,RP-ILD者需关注铁蛋白和中性粒细胞与淋巴细胞比值。
  • 抗MDA5皮肌炎病程中应警惕纵隔气肿,其提示高死亡风险。

局限性

  • 仅基于澳大利亚三州LIA检测人群,结果外推需谨慎。
  • 118例中仅108例有完整临床资料,存在资料不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In Australia, anti-MDA5 antibodies are exclusively tested by a line immunoblot assay (LIA). The clinical concordance of an LIA-positive anti-MDA5 result is unclear. We aimed to describe the clinical features and determine the clinical concordance of patients with anti-MDA5 antibodies. METHODS: Electronic records of a multisite cohort (patients with positive anti-MDA5 on LIA from three states in Australia from January 2017 to September 2024) were reviewed for clinical features of dermatomyositis (cutaneous manifestations, proximal weakness, interstitial lung disease [ILD]), laboratory investigations and other myositis autoantibodies, and imaging pertaining to the muscles and lungs. RESULTS: Complete clinical data were available for 108 of 118 patients with anti-MDA5 antibodies. A positive test was determined to be clinically concordant in 21 of 108 (19.4%) patients; these patients had higher signal intensity than those with clinical discordance (52 vs 19.5; P < 0.0001). The median age was 65 years (interquartile range 48-74), and 67% were female. The cohort was predominantly White (n = 14), followed by Southeast Asian (n = 3), African (n = 3), and Middle Eastern (n = 1). All 21 patients with anti-MDA5 dermatomyositis had ILD; 7 of 9 with rapidly progressive ILD (RP-ILD) were deceased at time of review. Patients with RP-ILD had higher ferritin levels (1,226 vs 262 μg/L; P < 0.05) and a higher neutrophil to lymphocyte ratio (4.1 vs 2.6; P < 0.05) than patients without RP-ILD. Pneumomediastinum developed in 7 of 21 (33%); of these, 6 had RP-ILD, and 4 subsequently died. Other manifestations included myositis (n = 8), cutaneous features (n = 14), polyarthritis (n = 6), and myocarditis (n = 1). CONCLUSION: Higher anti-MDA5 signal intensity on LIA was associated with greater clinical concordance. Pneumomediastinum is common and associated with high mortality.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Ali SB, Khoo T, Shivakumar K, et al. Clinical Characteristics and Concordance of Anti-MDA5 Antibodies: A Multicenter Australian Study. Arthritis Care Res (Hoboken). 2026. PMID: 42606144. doi:10.1002/acr.80144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。